177Lu-rhPSMA-10.1

N/A

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug Name177Lu-rhPSMA-10.1
Drug Alias NameLutetium-177 rhPSMA177Lu-radiohybrid-(rh)PSMA-theranostics177Lu-rh PSMA-theranostics177Lu-rhPSMA-10.1177Lu-rhPSMA10.1 +[13] 
ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionProstate-Specific Membrane Antigen modulatorsIonising radiation emittersPositron-emission tomography enhancers +[4] 
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic DiseasesProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTechnical University Munich
China Registration ClassN/A

Develop Information

Active CompaniesBlue Earth Therapeutics LtdThe University Of Texas MD Anderson Cancer CenterAveo Pharmaceuticals Inc +[5] 
Inactive CompaniesN/A
Active IndicationsProstatic DiseasesProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A